Women handled for high-grade cervical-intraepithelial-neoplasia (CIN) require long-term follow-up with high-risk human-papillomavirus (HPV) testing. Self-sampling for HPV is well-accepted amongst these sufferers, however its function in follow-up for this group requires investigation. The current research examined how effectively HPV findings from self-sampled vaginal (VSS) and urine specimens appropriately recognized girls from this cohort with recurrent CIN2+ in contrast with samples collected by clinicians. At 1st post-conization follow-up, 531 sufferers (99.8% participation) gave urine samples, carried out VSS, underwent colposcopy with punch biopsy of seen lesions and clinician-collected cervical sampling for HPV evaluation and liquid-based cytology.
A complete of 113 sufferers with optimistic HPV and/or irregular cytology at 1st follow-up underwent 2nd follow-up. At 1st follow-up, all sufferers with recurrent CIN3 had optimistic HPV outcomes by all strategies. Clinician sampling and VSS revealed HPV16 positivity in 50% of recurrent circumstances and urine sampling revealed HPV16 positivity in 25% of recurrent circumstances. At 2nd follow-up, all 7 newly-detected CIN2/three recurrences had been related to HPV positivity on VSS and clinician-samples. Only clinician-collected samples detected HPV positivity for two adenocarcinoma-in-situ recurrences, and each had been HPV18 optimistic.
A complete of 77 sufferers had irregular cytology at 1st follow-up, for which HPV positivity by way of VSS yielded highest sensitivity. The HPV findings had been optimistic from VSS in 12 sufferers with high-grade squamous-intraepithelial-lesions (HSIL), and 11 sufferers with HSIL had optimistic HPV findings in clinician-collected and urine samples. All strategies for assessing HPV presence yielded important age-adjusted odds ratios for predicting irregular lesions at 1st follow-up. For general HPV outcomes, Cohen’s kappa revealed substantial settlement between VSS and clinician sampling, and reasonable settlement between urine and clinician sampling. Clinician sampling and VSS had been extremely concordant for HPV16. Insofar as the pathology was squamous (not glandular), VSS appeared as delicate as clinician sampling for HPV in predicting final result among the many current cohort. Since VSS might be carried out at residence, this selection can maximize participation within the required long-term follow-up for these girls at high-risk.
What each dentist must find out about human papillomavirus
Human papillomavirus (HPV) has a practically ubiquitous prevalence inside the adolescent and grownup populations worldwide. The virus has been implicated for a long time in cervical and uterine cancers, however current information have proven a rise in circumstances of virally associated oropharyngeal squamous cell carcinoma in each female and male cohorts. The goal of this text is to overview the oral well being implications of HPV an infection, together with oral and oropharyngeal prevalence, manifestations, neoplastic potential of HPV-associated head and neck lesions, treatment modalities, and vaccine use.
The article may even focus on the persevering with training wants of oral healthcare suppliers. Dental professionals ought to routinely display screen sufferers for oral and oropharyngeal manifestations of HPV an infection, search well timed referral for therapeutic intervention of doubtlessly malignant lesions, and grow to be sturdy proponents of HPV vaccinations for at-risk sufferers. Human papillomavirus sort 16 (HPV-16) is the key HPV sort concerned in inflicting cervical most cancers amongst girls. The illness burden is excessive in creating and underdeveloped nations. Previously, the constitutive expression of HPV-16 L1 protein led to male sterility in transplastomic tobacco vegetation.
Here, the HPV-16 L1 gene was expressed in chloroplasts of Nicotiana tabacum beneath the management of an ethanol-inducible promoter, trans-activated by nucleus-derived sign peptide. Plants containing nuclear part had been remodeled with transformation vector pEXP-T7-L1 by biolistic gun. The transformation and homoplasmic standing of remodeled vegetation was verified by polymerase chain response (PCR) and Southern blotting, respectively. Protein was induced by spraying 5% ethanol for seven consecutive days. The appropriate folding of L1 protein was confirmed by antigen-capture ELISA utilizing a conformation-specific antibody. The L1 protein amassed as much as three μg/gm of contemporary plant materials.
Human Papillomavirus (HPV) Health Savings as an Alternative Solution: HPV Vaccination Behavior in Adolescents
This research aimed to measure the results of reproductive well being financial savings (tabungan kesehatan reproduksi, Takespro) on human papillomavirus (HPV) vaccine initiation program and the standard of the choice making to get vaccinated, as measured by data, attitudes, beliefs, and self-efficacy towards HPV vaccination. This quasi-experimental research was carried out on 128 college students randomly allotted to intervention and management teams. This analysis was carried out in junior excessive colleges.
The intervention group acquired the well being training “Takespro HPV” intervention by means of movies and booklets for 6 months at college. Participants within the management group acquired traditional care from the varsity. Data had been collected utilizing a questionnaire of data, attitudes, beliefs, and self-efficacy about HPV vaccination modified by researchers based mostly on earlier analysis and examined for validity and reliability. Data had been analyzed utilizing Mann-Whitney take a look at and impartial t-test.
Stathmin 1 / Oncoprotein 18 Antibody |
20-abx115844 |
Abbexa |
|
|
|
99445-18 DCT 18 X 150MM |
99445-18 |
CORNING |
125/pk |
EUR 97 |
Description: Disposable Culture Tubes; DCT's, CGW |
Stathmin/Metablastin/Oncoprotein 18 |
MO47065 |
Neuromics |
0.5 ml |
EUR 349 |
Human Papillomavirus 16 Oncoprotein E7 (HPV16-E7) Antibody |
abx414613-02mg |
Abbexa |
0.2 mg |
EUR 565 |
|
Human Papillomavirus 16 Oncoprotein E7 (HPV16-E7) Antibody |
abx414614-02mg |
Abbexa |
0.2 mg |
EUR 565 |
|
Recombinant Human Papillomavirus 18 |
7-07777 |
CHI Scientific |
100µg |
Ask for price |
Recombinant Human Papillomavirus 18 |
7-07778 |
CHI Scientific |
500µg |
Ask for price |
Recombinant Human Papillomavirus 18 |
7-07779 |
CHI Scientific |
1000µg |
Ask for price |
Papillomavirus type 18 Protein E7 Antibody |
20-abx110071 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
99999 CAP 18-415 |
99999-18 |
CORNING |
1000/pk |
EUR 295 |
Description: Disposable Screw Cap Culture Tubes; DSCCT's, Caps |
Mouse Anti Human Papillomavirus 16 Oncoprotein E7 Monoclonal Antibody |
CABT-51466MH |
Creative Diagnostics |
0.2 mg |
EUR 767 |
Human papillomavirus 18 PCR kit |
PCR-H464-48D |
Bioingentech |
50T |
EUR 453 |
Human papillomavirus 18 PCR kit |
PCR-H464-96D |
Bioingentech |
100T |
EUR 572 |
9998 SCREW CAP 415/18 |
9998-18 |
CORNING |
192/pk |
EUR 103 |
Description: General Apparatus; Stoppers |
Human Papillomavirus Type 18 (HPV 18) ELISA Kit |
abx052654-96tests |
Abbexa |
96 tests |
EUR 668 |
|
Papillomavirus type 18 Protein E7 Antibody (Biotin) |
20-abx105747 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Papillomavirus type 18 Protein E7 Antibody (FITC) |
20-abx107165 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Papillomavirus type 18 Protein E7 Antibody (HRP) |
20-abx108585 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Human papillomavirus 18 RT PCR kit |
RTq-H464-100D |
Bioingentech |
100T |
EUR 717 |
Human papillomavirus 18 RT PCR kit |
RTq-H464-150D |
Bioingentech |
150T |
EUR 808 |
Human papillomavirus 18 RT PCR kit |
RTq-H464-50D |
Bioingentech |
50T |
EUR 598 |
COVER GLASS, NO. 1, SQUARE 18 X 18MM |
2845-18 |
CORNING |
100/pk |
EUR 112 |
Description: Cover Glass; Cover Glass, CGW |
COVER GLASS, NO. 2, SQUARE 18 X 18MM |
2855-18 |
CORNING |
50/pk |
EUR 83 |
Description: Cover Glass; Cover Glass, CGW |
COVER GLASS, NO. 1 1/2, SQUARE 18 X 18MM |
2850-18 |
CORNING |
100/pk |
EUR 131 |
Description: Cover Glass; Cover Glass, CGW |
Human papillomavirus 18 One-Step PCR kit |
Oneq-H464-100D |
Bioingentech |
100T |
EUR 866 |
Human papillomavirus 18 One-Step PCR kit |
Oneq-H464-150D |
Bioingentech |
150T |
EUR 981 |
Human papillomavirus 18 One-Step PCR kit |
Oneq-H464-50D |
Bioingentech |
50T |
EUR 718 |
Human Papillomavirus Type 18 ?HPV18?ELISA Kit |
201-12-2024 |
SunredBio |
96 tests |
EUR 440 |
|
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids. |
Human papillomavirus type 18 L1 protein (L1) |
1-CSB-RP083594v |
Cusabio |
-
EUR 380.00
-
EUR 214.00
-
EUR 1309.00
-
EUR 560.00
-
EUR 873.00
-
EUR 262.00
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
Description: Recombinant Human papillomavirus type 18 L1 protein(L1),partial expressed in E.coli |
Human papillomavirus type 18 Protein E7 (E7) |
1-CSB-YP361948HMN |
Cusabio |
-
EUR 430.00
-
EUR 234.00
-
EUR 1508.00
-
EUR 642.00
-
EUR 1009.00
-
EUR 291.00
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
Description: Recombinant Human papillomavirus type 18 Protein E7(E7) expressed in Yeast |
Human papillomavirus type 18 Protein E7 (E7) |
1-CSB-EP361948HMN |
Cusabio |
-
EUR 380.00
-
EUR 214.00
-
EUR 1309.00
-
EUR 560.00
-
EUR 873.00
-
EUR 262.00
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
Description: Recombinant Human papillomavirus type 18 Protein E7(E7) expressed in E.coli |
Human papillomavirus type 18 (HPV18) antibody (IgM) ELISA kit |
CSB-EQ028067HU-24T |
Cusabio |
1 plate of 24 wells |
EUR 165 |
|
Description: Quantitativesandwich ELISA kit for measuring Human papillomavirus type 18 (HPV18) antibody (IgM) in samples from serum, plasma. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price. |
Human papillomavirus type 18 (HPV18) antibody (IgM) ELISA kit |
1-CSB-EQ028067HU |
Cusabio |
-
EUR 804.00
-
EUR 5099.00
-
EUR 2704.00
|
- 1 plate of 96 wells
- 10 plates of 96 wells each
- 5 plates of 96 wells each
|
|
Description: Quantitativesandwich ELISA kit for measuring Human papillomavirus type 18 (HPV18) antibody (IgM) in samples from serum, plasma. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits. |
Human Papillomavirus Type 18 L1 ?HPV18L1?ELISA Kit |
201-12-2025 |
SunredBio |
96 tests |
EUR 440 |
|
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids. |
Human papillomavirus type 18 Regulatory protein E2 (E2) |
1-CSB-YP361949HMN |
Cusabio |
-
EUR 430.00
-
EUR 234.00
-
EUR 1508.00
-
EUR 642.00
-
EUR 1009.00
-
EUR 291.00
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
Description: Recombinant Human papillomavirus type 18 Regulatory protein E2(E2) expressed in Yeast |
Human papillomavirus type 18 Regulatory protein E2 (E2) |
1-CSB-EP361949HMN |
Cusabio |
-
EUR 380.00
-
EUR 214.00
-
EUR 1309.00
-
EUR 560.00
-
EUR 873.00
-
EUR 262.00
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
Description: Recombinant Human papillomavirus type 18 Regulatory protein E2(E2) expressed in E.coli |
ELISA kit for Human papillomavirus type 18 (HPV18)antibody (IgG) |
EK0272 |
SAB |
96 tests |
EUR 712 |
Description: Enzyme-linked immunosorbent assay kit for quantification of Human papillomavirus type 18 (HPV18)antibody (IgG) in samples from serum, plasma, tissue homogenates and other biological fluids. |
Rabbit papillomavirus type 18 L1-capsids antibody(IgG)ELISA Kit |
CSB-E14280Rb-24T |
Cusabio |
1 plate of 24 wells |
EUR 165 |
|
Description: Quantitativesandwich ELISA kit for measuring Rabbit papillomavirus type 18 L1-capsids antibody (IgG) in samples from serum, plasma, cell culture supernates, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price. |
Rabbit papillomavirus type 18 L1-capsids antibody(IgG)ELISA Kit |
1-CSB-E14280Rb |
Cusabio |
-
EUR 900.00
-
EUR 5476.00
-
EUR 2900.00
|
- 1 plate of 96 wells
- 10 plates of 96 wells each
- 5 plates of 96 wells each
|
|
Description: Quantitativesandwich ELISA kit for measuring Rabbit papillomavirus type 18 L1-capsids antibody(IgG) in samples from serum, plasma, cell culture supernates, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits. |
Human Papillomavirus Type 18-IgG (HPV18-IgG) ELISA Kit |
abx051563-96tests |
Abbexa |
96 tests |
EUR 668 |
|
Human papillomavirus type 18 Minor capsid protein L2 (L2) |
1-CSB-YP356939HMN |
Cusabio |
-
EUR 430.00
-
EUR 234.00
-
EUR 1508.00
-
EUR 642.00
-
EUR 1009.00
-
EUR 291.00
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
Description: Recombinant Human papillomavirus type 18 Minor capsid protein L2(L2) expressed in Yeast |
Human papillomavirus type 18 Minor capsid protein L2 (L2) |
1-CSB-EP356939HMN |
Cusabio |
-
EUR 380.00
-
EUR 214.00
-
EUR 1309.00
-
EUR 560.00
-
EUR 873.00
-
EUR 262.00
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
Description: Recombinant Human papillomavirus type 18 Minor capsid protein L2(L2) expressed in E.coli |
ELISA kit for Rabbit Papillomavirus type 18 L1-capsids IgG antibody |
KTE90138-48T |
Abbkine |
48T |
EUR 354 |
|
Description: Quantitative sandwich ELISA for measuring Rabbit Papillomavirus type 18 L1-capsids IgG antibody in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids. |
ELISA kit for Rabbit Papillomavirus type 18 L1-capsids IgG antibody |
KTE90138-5platesof96wells |
Abbkine |
5 plates of 96 wells |
EUR 2252 |
|
Description: Quantitative sandwich ELISA for measuring Rabbit Papillomavirus type 18 L1-capsids IgG antibody in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids. |
ELISA kit for Rabbit Papillomavirus type 18 L1-capsids IgG antibody |
KTE90138-96T |
Abbkine |
96T |
EUR 572 |
|
Description: Quantitative sandwich ELISA for measuring Rabbit Papillomavirus type 18 L1-capsids IgG antibody in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids. |
Human papillomavirus type 18 L1-capsids(HPV18L1) antibody (IgG) ELISA kit |
CSB-EQ027476HU-24T |
Cusabio |
1 plate of 24 wells |
EUR 165 |
|
Description: Qualitative indirect ELISA kit for measuring Human papillomavirus type 18 L1-capsids (HPV18L1) antibody (IgG) in samples from serum, plasma. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price. |
Human papillomavirus type 18 L1-capsids(HPV18L1) antibody (IgG) ELISA kit |
1-CSB-EQ027476HU |
Cusabio |
-
EUR 602.00
-
EUR 4238.00
-
EUR 2256.00
|
- 1 plate of 96 wells
- 10 plates of 96 wells each
- 5 plates of 96 wells each
|
|
Description: Qualitative indirect ELISA kit for measuring Human papillomavirus type 18 L1-capsids(HPV18L1) antibody (IgG) in samples from serum, plasma. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits. |
FT4 (Free thyroxine) ELISA test |
18 |
Biobase |
96T/Box |
Ask for price |
|
Description: ELISA based test for quantitative detection of FT4 (Free thyroxine) |
ELISA kit for Human papillomavirus type 18 L1-capsids (HPV18L1) antibody (IgG) |
EK0271 |
SAB |
96 tests |
EUR 712 |
Description: Enzyme-linked immunosorbent assay kit for quantification of Human papillomavirus type 18 L1-capsids (HPV18L1) antibody (IgG) in samples from serum, plasma, tissue homogenates and other biological fluids. |
Goat polyclonal antibody for Papillomavirus |
5001 |
Virostat |
1 ml |
EUR 316.44 |
Description: This is goat polyclonal antibody against Papillomavirus group for WB, ELISA. |
Mouse antibody for Bovine Papillomavirus |
5091 |
Virostat |
100 ug |
EUR 321.88 |
Description: This is purified Mouse monoclonal antibody against Bovine Papillomavirus for WB, ELISA. |
Mouse antibody for Bovine Papillomavirus |
5095 |
Virostat |
100 ug |
EUR 321.88 |
Description: This is purified Mouse monoclonal antibody against Bovine Papillomavirus for WB, ELISA. |
Goat polyclonal antibody for Papillomavirus |
6124 |
Virostat |
1 ml |
EUR 321.88 |
Description: This is HRP conjugated goat polyclonal antibody against Papillomavirus group for WB, ELISA. |
Papillomavirus 16 Protein |
20-abx260289 |
Abbexa |
-
EUR 885.00
-
EUR 342.00
-
EUR 1609.00
|
|
|
Papillomavirus 6 Protein |
20-abx260291 |
Abbexa |
-
EUR 885.00
-
EUR 342.00
-
EUR 1609.00
|
|
|
Papillomavirus 11 Protein |
20-abx260292 |
Abbexa |
-
EUR 885.00
-
EUR 342.00
-
EUR 1609.00
|
|
|
Anti-c-Myc Oncoprotein Monoclonal Antibody |
M00026 |
BosterBio |
100ug/vial |
EUR 397 |
Description: Mouse Monoclonal c-Myc Oncoprotein Antibody. Validated in IHC and tested in Human. |
Oncoprotein Induced Transcript 3 (OIT3) Antibody |
20-abx130349 |
Abbexa |
-
EUR 439.00
-
EUR 133.00
-
EUR 1233.00
-
EUR 592.00
-
EUR 328.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Oncoprotein Induced Transcript 3 (OIT3) Antibody |
20-abx103361 |
Abbexa |
-
EUR 411.00
-
EUR 133.00
-
EUR 1149.00
-
EUR 565.00
-
EUR 314.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNCA1269-250 |
Biotium |
250uL |
EUR 383 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), APC conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNC811269-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF680R conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNC811269-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF680R conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNCAP1269-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNCAP1269-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNCB1269-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), Biotin conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNCB1269-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), Biotin conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNC471269-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF647 conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNC471269-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF647 conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNC551269-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF555 conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNC551269-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF555 conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNC431269-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF543 conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNC431269-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF543 conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNC881269-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF488A conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNC881269-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF488A conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNC941269-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF594 conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNC941269-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF594 conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNCH1269-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNCH1269-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNCP1269-250 |
Biotium |
250uL |
EUR 383 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), PerCP conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNC041269-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF405S conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNC041269-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF405S conjugate, Concentration: 0.1mg/mL |
Oncoprotein Induced Transcript 3 (OIT3) Antibody |
20-abx173889 |
Abbexa |
|
|
|
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNCR1269-250 |
Biotium |
250uL |
EUR 383 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), RPE conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNUB1269-100 |
Biotium |
100uL |
EUR 209 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), Concentration: 0.2mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNUB1269-500 |
Biotium |
500uL |
EUR 458 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), Concentration: 0.2mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNC681269-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF568 conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNC681269-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF568 conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNC701269-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF770 conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNC701269-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF770 conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNC051269-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF405M conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNC051269-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF405M conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNC611269-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF660R conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNC611269-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF660R conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNC401269-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF640R conjugate, Concentration: 0.1mg/mL |
c-Myc Oncoprotein (MYC275 + MYC909) Antibody |
BNC401269-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF640R conjugate, Concentration: 0.1mg/mL |
A complete of 40 contributors had been actively enrolled within the intervention group, and 88 had been passively enrolled within the management group. The well being training that was half of the Takespro HPV intervention improved the data (p < 0.05) and self-efficacy (p < 0.05) of the intervention group in contrast with the management group. The perspective and perception variables confirmed no important distinction (p > 0.05). Forty college students exhibited the well being copy financial savings conduct at colleges. However, the financial savings quantity was inadequate to get HPV vaccination on the initiation part.